Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 49 of 6351
-
Magic mushroom compound could help treat anorexia in young adults
Disease control Recruiting nowThe goal of this clinical trial is to learn if psilocybin, given with psychological support, is safe and helps treat anorexia nervosa in young adults. Anorexia nervosa is a serious eating disorder that currently has no approved medicine. Psilocybin is a psychedelic substance that…
Phase 2 • Sponsor: Region Skane • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Gene therapy breakthrough? new trial targets rare brain disorder FOXG1
Disease control By invitation onlyThe goal of this clinical trial is to learn if FRF-001 is a safe, tolerable, and efficacious treatment for children and adults with FOXG1 syndrome.
Phase 1/2 • Sponsor: FOXG1 Research Foundation • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
In-Womb procedure aims to save babies from deadly brain malformation
Disease control Recruiting nowThis is a prospective, single-arm non-randomized interventional study of fetuses to assess the efficacy and safety of fetal embolization of VOGM. Subjects will receive a one-time study intervention of fetal embolization, at or after 34 weeks of gestation. After delivery, neurolog…
Sponsor: Darren Orbach • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could a 'Sandwich' of drugs beat Full-Course immunotherapy for a tough head and neck cancer?
Disease control Recruiting nowImmunotherapy combined with chemoradiotherapy has become standard care for locally advanced nasopharyngeal carcinoma, yet radiotherapy-induced lymphopenia may impair the efficacy of concurrent PD-1 blockade. Existing evidence supports synergistic anti-tumor activity between the a…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Triple immunotherapy cocktail aims to boost surgery success in liver cancer
Disease control Not yet recruitingThe purpose of this phase Ib/II multicenter randomized control study is to investigate the efficacy and safety of peri-operative treatment with combination of CTLA-4, PD-1 antibodies and bevacizumab in resectable HCC
Phase 1/2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Breath of life: new test could sniff out gut cancers before they spread
Diagnosis Not yet recruitingThe investigators of this study are developing a simple breath test to help detect gastrointestinal (gut) cancers earlier, including cancers of the oesophagus (food pipe), stomach, pancreas, liver and bowel. These cancers often cause non-specific symptoms that are similar to beni…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
Can an immunotherapy drug replace surgery for some endometrial cancers?
Cure Not yet recruitingTo investigate the efficacy and safety of immune checkpoint inhibitors as a non-surgical (surgery-avoiding) treatment in patients with stage I-II MSI-H/dMMR endometrial cancer.
Phase 2 • Sponsor: Wang Jianliu • Aim: Cure
Last updated Jul 30, 2026 00:00 UTC
-
Tweaking the Heart-Lung machine: a new strategy to prevent Post-Surgery strokes and clots?
Disease control Not yet recruitingType A acute aortic dissection (TAAAD) is a life-threatening disease that typically requires emergency surgery to prevent rupture from causing major bleeding events, with insufficient attention paid to its thromboembolic events. Although measures to avoid bleeding during the peri…
Sponsor: Xiangya Hospital of Central South University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
Disease control Not yet recruitingSystemic light-chain (AL) amyloidosis is a plasma cell disorder characterized by the production of misfolded immunoglobulin light chains that deposit in organs and lead to progressive organ dysfunction. Although daratumumab-based therapy has improved outcomes, a substantial propo…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a diabetes drug help heart failure patients walk farther?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if tirzepatide works to improve physical function in adults with heart failure and obesity. It will also learn about the safety of tirzepatide. The main questions it aims to answer are: Does tirzepatide improve how far participants can…
Phase 3 • Sponsor: Shahid Beheshti University of Medical Sciences • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Daily pill aims to tackle weight and diabetes together
Disease control Recruiting nowThis is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 7…
Phase 3 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New radiation rhythm may outsmart glioblastoma and save memory
Disease control Recruiting nowThis phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma. After completion of surgery, the standard of care for glioblastoma is radiation t…
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Can a Two-Drug cocktail keep bladder cancer from coming back?
Disease control Recruiting nowPurpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after radical resection. Study details: Duration: \~78 months (6.5 years) from FSI to last subject visit Treatment length: up t…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New combo therapy aims to shrink rectal tumors and save organs
Disease control Not yet recruitingThis is a prospective, multicenter, randomized controlled trial aimed at comparing different radiotherapy fractionation regimens combined with sequential dual immunotherapy versus traditional chemoradiotherapy in neoadjuvant treatment for locally advanced rectal cancer (LARC). A …
Phase 2/3 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Triple threat against pancreatic cancer: radiation, immunotherapy, and chemotherapy combined
Disease control Not yet recruitingThis is a Phase II, prospective, single-arm exploratory clinical trial designed to evaluate the efficacy and safety of stereotactic body radiotherapy followed by ipilimumab N01 plus sintilimab in combination with nab-paclitaxel and gemcitabine in patients with locally advanced pa…
Phase 2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
AI reads MRI scans to reveal hidden brain tumor types in children before surgery
Diagnosis Not yet recruitingThis multicenter observational cohort study aims to develop and validate an artificial intelligence (AI)-assisted diagnostic system for preoperative molecular subtyping of pediatric brain tumors using routine magnetic resonance imaging (MRI). The study will include seven major pe…
Sponsor: Huashan Hospital • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
Timing of local therapy may boost immunotherapy in Hard-to-Treat esophageal cancer
Disease control Recruiting nowAlthough immunotherapy combined with chemotherapy has become the first-line standard regimen for advanced esophageal squamous cell carcinoma (ESCC) and improved clinical outcomes in advanced patients, the prognosis of patients with esophageal cancer remains unsatisfactory, with a…
Sponsor: Fudan University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children with inoperable or progressive tumors.
Phase 2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a chemo-free cocktail tame mantle cell lymphoma?
Disease control Recruiting nowThis study aims to evaluate the safety and efficacy of orelabrutinib (O) in combination with obinutuzumab (G) and short-course venetoclax (V) in patients with treatment-naïve MCL.
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Gene therapy hope for babies with fatal muscle disease
Disease control Recruiting nowThis is a phase I/II clinical study to evaluate the safety, preliminary efficacy and immunogenicity of SKG0201 injection in subjects with Spinal Muscular Atrophy Type I.
Phase 1/2 • Sponsor: Lanyue Biotech (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC